Hudson Bay Capital Management
ZNTL icon

Hudson Bay Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Hudson Bay Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
+117,127
New +$302K ﹤0.01% 1049
2025
Q3 		– Sell
-16,638
Closed -$19.3K – 1734
2025
Q2 		$19.3K Buy
+16,638
New +$21.9K ﹤0.01% 1311

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Hudson Bay Capital Management's ZNTL Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 117,127 shares worth $274K. The stake represents ﹤0.01% of the portfolio and ranks #1049 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in ZNTL as recently as Q2 2025.

Hudson Bay Capital Management first reported a position in ZNTL in Q2 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Hudson Bay Capital Management held 117,127 shares of Zentalis Pharmaceuticals worth $274K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Hudson Bay Capital Management position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1049 holding.
  • Hudson Bay Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.